The expanded facility will enhance Singapore’s biopharmaceutical manufacturing capabilities, producing innovative treatments and offering high-skilled career opportunities.SINGAPORE: Pfizer’s newly expanded Active Pharmaceutical Ingredient (API) manufacturing facility in Tuas Biomedical Park, with an investment of S$1 billion (US$743 million), was officially opened on Tuesday (Jul 23). The state-of-the-art extension is set to create more than 250 …